Ausgabe 2/2024
Inhalt (8 Artikel)
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
Giovany Orozco-Leal, Eugenie Evelynne Johnson, Sedighe Hosseinijebeli, Tomos Robinson, Tara Homer, Claire H. Eastaugh, Catherine Richmond, Louise Tanner, Nick Meader, Ryan Kenny, Sheila A. Wallace, Stephen Rice
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
Daniel Gladwell, Oriana Ciani, Adam Parnaby, Stephen Palmer
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments
Alex J. Turner, Cormac Sammon, Nick Latimer, Blythe Adamson, Brennan Beal, Vivek Subbiah, Keith R. Abrams, Joshua Ray
Systematic Review of the Relative Social Value of Child and Adult Health
Tessa Peasgood, Martin Howell, Rakhee Raghunandan, Amber Salisbury, Marcus Sellars, Gang Chen, Joanna Coast, Jonathan C. Craig, Nancy J. Devlin, Kirsten Howard, Emily Lancsar, Stavros Petrou, Julie Ratcliffe, Rosalie Viney, Germaine Wong, Richard Norman, Cam Donaldson
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects
Ramesh Lamsal, E. Ann Yeh, Eleanor Pullenayegum, Wendy J. Ungar
Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study
Javier Mar, Oliver Ibarrondo, Carlo Delfin S. Estadilla, Nico Stollenwerk, Fernando Antoñanzas, Rubén Blasco-Aguado, Igor Larrañaga, Joseba Bidaurrazaga, Maíra Aguiar
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
Christopher W. Yee, Michael J. Harvey, Yiqiao Xin, Noam Y. Kirson